跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AREXVY POLVO Y SUSPENSION PARA SUSPENSION INYECTABLE - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
AREXVY POLVO Y SUSPENSION PARA SUSPENSION INYECTABLE
Approved
STANDARD
AREXVY POLVO Y SUSPENSION PARA SUSPENSION INYECTABLE
Glaxosmithkline Biologicals
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Jun 12, 2023
Approval ID
e88a9700de9ce080
Company
Glaxosmithkline Biologicals
Type
Standard
Approval Details
Approval Id
e88a9700de9ce080
Drug Cima Aemps Name
AREXVY POLVO Y SUSPENSION PARA SUSPENSION INYECTABLE
Register Number
1231740001
Holder Company Name
Glaxosmithkline Biologicals
Marketing Company Name
Glaxosmithkline S.A.
Holder Company Detail Path
/organization/glaxosmithkline-biologicals
Marketing Company Detail Path
/organization/glaxosmithkline-sa
Authorization Date
2023-06-12
Dosage Form
POLVO Y SUSPENSIÓN PARA SUSPENSIÓN INYECTABLE
Dose
0,5 ML
Route Of Administration
VÍA INTRAMUSCULAR
Prescription Type
Medicamento Sujeto A Prescripción Médica
Commercialized
Yes
Company Name
Glaxosmithkline Biologicals
Company Detail Path
/organization/glaxosmithkline-biologicals
Company Information
Pharmaceutical Company Name
GLAXOSMITHKLINE BIOLOGICALS
Country Name
France
City Name
st amand les eaux,hauts de france,country_fr
Address
637 RUE DES AULNOIS
Active Ingredients
VACUNA (RSVPREF) DE SUBUNIDAD F ESTABILIZADA EN PREFUSION FRENTE AL VIRUS RESPIRATORIO SINCITIAL.
120 µg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Jun 12, 2023
Approval ID
e88a9700de9ce080
Type
Standard
Back to CIMA-AEMPS Approvals
